Mary McGrae McDermott
Works at
Assistant professor
Sources: reporter.nih.gov
Grants and prizes
National Heart, Lung, and Blood Institute
UH3, IMProving mobility After revasCularizaTion in Peripheral Artery Disease: the IMPACT PAD Trial, UH3HL169565, 2024–2031, 16 Sept 2026
R21, Urolithin A to Improve Mitochondria and Mobility in Peripheral Artery Disease: Urolithin for PAD Trial, R21AG098116, 2026–2028, 7 Sept 2026
R01, Response to Exercise and Nitric Oxide in PAD: the RESIST PAD Trial, R01AG078614, 2023–2028, 14 Aug 2026
R01, Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD, R01AG076577, 2022–2027, 7 Jul 2026
R01, NICotinamidE riboside to improve functioning in PAD: The NICE Trial, R01AG090846, 2026–2031, 20 Mar 2026
National Heart, Lung, and Blood Institute
UH3, 1/2 + PROmote weight loss in obese PAD patients to preVEnt mobility loss: the PROVE Trial, UH3HL141729, 2019–2027, 14 Jul 2025
R21, Far Red Light to Improve Functioning in PAD: the LIGHT PAD Trial, R21AG080426, 2023–2026, 30 Jan 2024
R21, FIsetin to Reduce Senescence and mobility impairmenT in PAD: the FIRST Pilot Randomized Trial, R21AG075613, 2022–2027, 14 Jul 2023
Sources: reporter.nih.gov